Today: 19 May 2026
Browse Category

Biotechnology 3 December 2025 - 8 December 2025

Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics shares surged 101% to $69.46 on December 8 after reporting positive Phase 2b data for aleniglipron, its oral GLP-1 agonist for obesity. Patients on 120 mg lost 12.1% of body weight at 36 weeks versus 0.8% for placebo. The company held $799 million in cash as of September 30.
8 December 2025
···
Recursion Pharmaceuticals (RXRX) Stock Jumps on Positive FAP Trial Data: Latest News, AI Drug Discovery Outlook and Analyst Forecasts

Recursion Pharmaceuticals (RXRX) Stock Jumps on Positive FAP Trial Data: Latest News, AI Drug Discovery Outlook and Analyst Forecasts

Recursion Pharmaceuticals reported Phase 1b/2 trial data showing its AI-discovered drug REC-4881 reduced polyp burden by a median 43% at 13 weeks in patients with familial adenomatous polyposis. Shares rose as much as 6% pre-market before settling in the mid-$4 range. Most patients maintained or improved reductions after stopping treatment. No approved drugs currently exist for this condition.
8 December 2025
···
SELLAS Life Sciences (SLS) Stock on December 8, 2025: ASH 2025 Data, Cash Runway and Analyst Targets Over $6

SELLAS Life Sciences (SLS) Stock on December 8, 2025: ASH 2025 Data, Cash Runway and Analyst Targets Over $6

SELLAS Life Sciences (NASDAQ: SLS) traded at $1.74 per share as of 09:13 UTC on December 8, 2025, following new Phase 2 data for its SLS009 drug in relapsed/refractory AML-MR. The study showed a 46% overall response rate in 35 patients, with no dose-limiting toxicities or treatment-related deaths reported. The company plans to expand trials to newly diagnosed high-risk AML in early 2026.
8 December 2025
··
Vertex Pharmaceuticals (VRTX) Stock on December 7, 2025: Casgevy Breakthrough, Pain-Drug Setbacks and What 2026 Forecasts Are Saying

Vertex Pharmaceuticals (VRTX) Stock on December 7, 2025: Casgevy Breakthrough, Pain-Drug Setbacks and What 2026 Forecasts Are Saying

Vertex Pharmaceuticals shares closed at $455.48 on December 5, 2025, valuing the company at about $115–116 billion. New data presented December 6 showed CASGEVY gene therapy achieved 12-month crisis- and transfusion-free outcomes in children 5–11 with sickle cell disease and beta thalassemia, though one pediatric patient died from transplant complications. Vertex plans global regulatory filings for this age group in early 2026.
7 December 2025
····
CRISPR Therapeutics (CRSP) Stock on 7 December 2025: Latest Price, News, Forecasts and Gene‑Editing Outlook

CRISPR Therapeutics (CRSP) Stock on 7 December 2025: Latest Price, News, Forecasts and Gene‑Editing Outlook

CRISPR Therapeutics closed at $56.88 on December 5, giving the company a market cap near $5.9 billion. The State Board of Administration of Florida Retirement System disclosed a new $1.04 million stake. Q3 results showed a net loss of $106.4 million on $0.89 million in revenue. About 69% of shares are now held by institutions and hedge funds.
7 December 2025
··
INO Stock: Inovio’s FDA BLA Milestone, New Equity Offerings and 2026 Catalyst – Latest News and Forecasts (December 7, 2025)

INO Stock: Inovio’s FDA BLA Milestone, New Equity Offerings and 2026 Catalyst – Latest News and Forecasts (December 7, 2025)

Inovio Pharmaceuticals closed at $2.07 on December 5, up 2.5% for the day and nearly 20% over the past 10 sessions, with volume near 1 million shares. The stock recently crossed its 200-day moving average, while short interest remains high at 34% of daily volume. Wall Street’s average 12-month price target is $9, despite continued losses and minimal revenue.
7 December 2025
···
Moderna (MRNA) Stock Jumps on Vaccine Safety Study and $1.5B Lifeline: Latest News and Forecasts as of December 6, 2025

Moderna (MRNA) Stock Jumps on Vaccine Safety Study and $1.5B Lifeline: Latest News and Forecasts as of December 6, 2025

Moderna shares closed at $27.70 on December 5, up 8.7% on volume over 16 million. The rally followed a major French study showing no increase in long-term mortality from mRNA COVID vaccines and a new $1.5 billion credit facility. The stock is still down more than 50% over the past year despite recent gains. Year-to-date performance remains negative at –38.7%.
6 December 2025
··
Moderna (MRNA) Stock Jumps on New Vaccine Safety Data – Latest News, Forecast & Analysis for December 5, 2025

Moderna (MRNA) Stock Jumps on New Vaccine Safety Data – Latest News, Forecast & Analysis for December 5, 2025

Moderna shares jumped nearly 9% on December 5, closing at about $27–28 after a large French study backed the long-term safety and effectiveness of mRNA COVID vaccines. The stock remains down roughly 34% year-to-date and trades around 40% below its 52-week high. Investors also weighed a new $1.5 billion loan deal and updated guidance on future growth.
5 December 2025
··
Aditxt (ADTX) Stock on December 5, 2025: BitXbio Pivot, Reverse Split and Survival Risk Explained

Aditxt (ADTX) Stock on December 5, 2025: BitXbio Pivot, Reverse Split and Survival Risk Explained

Aditxt (NASDAQ: ADTX) traded around $3 per share midday December 5, 2025, with a market cap near $1.7 million and only 559,000 shares outstanding. The company reported $2,770 in revenue and a $37.6 million net loss for the first nine months of 2025, holding $163,041 in cash as of September 30. ADTX faces ongoing Nasdaq delisting risk after a 1-for-113 reverse split. Trading remains volatile with heavy short interest.
5 December 2025
··
SciSparc (SPRC) Stock on December 5, 2025: Price Action, Quantum Data Deal, GERD Device Pivot and 2030 Forecast

SciSparc (SPRC) Stock on December 5, 2025: Price Action, Quantum Data Deal, GERD Device Pivot and 2030 Forecast

SciSparc Ltd. shares closed at $1.80 on December 5, 2025, after surging on volume above 10 million, following news of a quantum bio-data analytics deal via its NeuroThera subsidiary. The stock remains down over 70% in the past year and trades more than 95% below its 52-week high of $37.59, leaving the company with a market cap near $5.8 million.
5 December 2025
···
Picard Medical (PMI) Stock Soars 82% After Artificial Heart Breakthrough: Is This Rally Sustainable?

Picard Medical (PMI) Stock Soars 82% After Artificial Heart Breakthrough: Is This Rally Sustainable?

Picard Medical shares jumped 83% to $3.69 on December 4 after new data on its Emperor Total Artificial Heart was presented at ISMCS 2025 in Vienna. Trading volume soared to nearly 39 million shares. The company’s market cap reached $272 million, but the stock remains down over 70% from its October high of $13.68. After-hours trading showed some profit-taking, with prices around $3.30–$3.40.
5 December 2025
···
Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now

Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now

Polyrizon shares surged over 100% to the mid-teens on December 4, 2025, with volume topping 26 million after announcing a manufacturing milestone for its PL‑14 Allergy Blocker and promising preclinical data for its naloxone hydrogel. The stock saw heavy volatility and mixed analyst signals, with “Strong Sell” ratings alongside momentum-driven “Buy” calls. The Israel-based biotech has no approved products.
4 December 2025
···
CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors

CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors

CRISPR Therapeutics shares surged 8.5% to $56 on December 3, landing mid-range between their 52-week low of $30 and high of $78. The company reported a $106 million Q3 net loss on $0.9 million in revenue but holds $1.9 billion in cash. Takeover rumors persist, though no formal bids have emerged. Wall Street price targets range widely, with consensus in the high-$60s to mid-$70s.
4 December 2025
·
Capricor Therapeutics (CAPR) Soars After HOPE‑3 Win: Latest News, Analyst Targets and Stock Forecast as of December 4, 2025

Capricor Therapeutics (CAPR) Soars After HOPE‑3 Win: Latest News, Analyst Targets and Stock Forecast as of December 4, 2025

Capricor Therapeutics shares surged over 300% to nearly $30 after Phase 3 data showed its Deramiocel cell therapy slowed upper-limb decline by 54% and preserved 91% of heart function in Duchenne muscular dystrophy patients. The HOPE-3 trial enrolled 106 mostly non-ambulatory boys and young men. Trading was volatile, with the stock flagged as “extremely overbought.”
4 December 2025
··
Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb shares jumped over 6% to $51.32 intraday on December 3, 2025, after the company announced a data review and patient re-enrollment for its ADEPT-2 Alzheimer’s psychosis trial. The stock rally follows strong Q3 results and analyst upgrades, despite ongoing legal risks and looming patent expiries.
3 December 2025
····
Capricor Therapeutics (CAPR) Stock Skyrockets on HOPE‑3 Win: FDA Path, Price Targets and 2026 Outlook

Capricor Therapeutics (CAPR) Stock Skyrockets on HOPE‑3 Win: FDA Path, Price Targets and 2026 Outlook

Capricor Therapeutics shares jumped over 380% Wednesday after reporting positive Phase 3 HOPE-3 trial results for deramiocel in Duchenne muscular dystrophy. The stock opened near $30, up from $6.36, hitting intraday highs around $40 on volume over 40 million shares. The FDA previously rejected deramiocel but will review new data for possible approval in 2026. Capricor ended Q3 with $98.6 million in cash.
3 December 2025
···
Capricor Therapeutics (NASDAQ: CAPR) Soars Over 500% After HOPE‑3 Phase 3 Win: What It Means for the Stock Now

Capricor Therapeutics (NASDAQ: CAPR) Soars Over 500% After HOPE‑3 Phase 3 Win: What It Means for the Stock Now

Capricor Therapeutics shares surged over 500% on December 3, 2025, after its Phase 3 HOPE‑3 trial of Deramiocel in Duchenne muscular dystrophy met all primary and key secondary endpoints. The trial showed a 54% slowing of upper limb decline and 91% preservation of heart function versus placebo. Capricor plans to resubmit its BLA to the FDA, addressing a previous Complete Response Letter. The stock traded around $39–40 intraday, up from $6.36.
3 December 2025
···
Polyrizon Ltd (PLRZ) Stock Soars on Nasal Spray Milestone: Latest News, AI Forecasts and Risk Outlook – December 3, 2025

Polyrizon Ltd (PLRZ) Stock Soars on Nasal Spray Milestone: Latest News, AI Forecasts and Risk Outlook – December 3, 2025

Polyrizon Ltd shares surged 130% on December 2 after announcing a manufacturing upscaling milestone for its PL‑14 nasal allergy blocker. The stock closed at $7.33, up from $3.16, with trading volume near 150 million shares. The Israeli biotech, which has no approved products or revenue, now trades around $6 pre-market. Polyrizon develops intranasal hydrogel sprays and remains in the pre-commercial stage.
3 December 2025
··
1 … 9 10 11 12 13 … 17

Stock Market Today

  • Essent Group (ESNT) Shows Potential Undervaluation Amid Mortgage Insurance Sector Focus
    May 19, 2026, 1:39 AM EDT. Essent Group (ESNT) trades near $62, showing flat returns over 30 days but up 6.6% annually. Recent sector attention highlights its role in U.S. mortgage insurance amid shifting credit and housing conditions. An Excess Returns analysis, comparing return on equity against cost of equity and projecting future profits, values ESNT at around $109.79, implying it is approximately 43.5% undervalued. The valuation considers a book value of $61.20 and stable EPS projections of $6.07. This suggests potential for market re-rating if fundamentals align with assumptions, offering an attractive risk-reward profile for investors focused on the diversified financial sector.

Latest articles

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

19 May 2026
Dominion Energy shares jumped 9.4% after agreeing to an all-stock merger with NextEra Energy, whose shares fell 4.6%. The S&P 500 slipped 0.1% and the Nasdaq dropped 0.5% as investors sold technology stocks amid rising Treasury yields and oil prices. Nvidia fell 1.4% ahead of earnings. U.S. crude settled at $107.37, and the 10-year Treasury yield reached 4.59%.
XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

19 May 2026
XP Inc.’s U.S.-listed shares fell 3.78% in after-hours trading Monday after reporting higher Q1 profit but weaker net inflows and a lower retail take rate. Net income rose 7% to 1.32 billion reais, but net inflow dropped to 14 billion reais from 24 billion a year earlier. The company declared a $0.20 dividend and announced a new CFO, Gustavo Alejo Viviani, starting August 3.
LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

19 May 2026
Publicis Groupe agreed to buy LiveRamp Holdings for $38.50 a share in cash, valuing the U.S. data-collaboration firm at $2.546 billion. LiveRamp stock jumped to $37.77 on the news, while the broader market fell. LiveRamp reported fiscal Q4 revenue of $206 million, up 9% from a year earlier. Publicis said the deal will boost its adjusted earnings per share from the first year after closing.

Popular

Nvidia Stock Slips Ahead of Earnings as Wall Street Eyes $5 Trillion Mark

Nvidia Stock Slips Ahead of Earnings as Wall Street Eyes $5 Trillion Mark

18 May 2026
Nvidia shares fell 2.8% to $219.05 on Monday ahead of its fiscal first-quarter results due Wednesday. AMD dropped 3.0% and Broadcom lost 2.2%, weighing on chip stocks. The Philadelphia Semiconductor Index slid 3.8% as investors booked profits and Treasury yields rose. Analysts expect Nvidia to report $78.5 billion in quarterly revenue, with data center sales in focus.
Go toTop